相关实验视频

Updated: Jul 26, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

高剂量率支臂治疗作为单一疗法与促进不利的中期风险局部性前列腺癌:匹配对分析

Benjamin D Willen¹, Kamran Salari¹, Andrew H Zureick¹

¹Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

|June 16, 2023

概括

高剂量率支架疗法单疗法 (HDR-M) 对不利的中期风险前列腺癌有效,表现出类似于HDR支架疗法增强 (HDR-B) 的结果,但胃肠道副作用较少.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
尿道瘤学尿道瘤学

背景情况:

高剂量率支臂治疗 (HDR-B) 是中等风险前列腺癌的治疗选择.
不利的中等风险前列腺癌需要仔细选择治疗.
在UIR患者中,HDR-M单疗法与HDR-B增强疗法 (HDR-B) 的直接比较数据有限.

研究的目的:

在UIR前列腺癌患者中,比较HDR-M与HDR-B的疗效和毒性.
评估瘤结果,包括整体存活率 (OS),癌症特异性存活率 (CSS),远程转移 (DM),局部复发 (LRR) 和无生物化学失败 (FFBF).
评估两种治疗方法的急性和慢性毒性概况.

主要方法:

在1997年至2020年期间接受治疗的UIR前列腺癌患者的回顾性分析.
根据年龄,格里森得分和临床T阶段对HDR-M和HDR-B队列的匹配.
生物化学失败定义为PSA nadir (nPSA) + 2 ng/mL;毒性数据收集并报告.

主要成果:

分析了70个匹配对 (140名患者);HDR-M的中位随访时间为5.2年,HDR-B的9.3年.
在HDR-M和HDR-B之间在OS,CSS,DM,LRR或FFBF中没有发现显著差异.
HDR-B与较高的急性2级+胃肠道毒性,急性失尿症和腹相关;慢性毒性类似.

结论:

高射激光支臂疗法单疗法是选择UIR前列腺癌患者的有效治疗方法.
与HDR-B相比,HDR-M提供了更有利的胃肠道毒性概况.
建议进行进一步的前性试验,以优化对这些异质UIR前列腺癌队列的患者选择.

关键词:

支臂疗法是一种手臂疗法.这就是HDR HDR.中间风险是中间风险.前列腺癌是什么意思前列腺癌是什么意思

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...